DOCSLIB.ORG

Known Bioactive Library: Microsource 1 - US Drug Collection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Known Bioactive Library: Microsource 1 - US Drug Collection ICCB-L ICCB-L Vendor Vendor Compound Name Bioactivity Source CAS Plate Well ID antifungal, inhibits Penicillium 2091 A03 Microsource 00200046 GRISEOFULVIN 126-07-8 mitosis in metaphase griseofulvum 3505-38-2, 486-16-8 2091 A04 Microsource 01500161 CARBINOXAMINE MALEATE antihistaminic synthetic [carbinoxamine] 2091 A05 Microsource 00200331 SALSALATE analgesic synthetic 552-94-3 muscle relaxant 2091 A06 Microsource 01500162 CARISOPRODOL synthetic 78-44-4 (skeletal) antineoplastic, 2091 A07 Microsource 00210369 GALLIC ACID insect galls 149-91-7 astringent, antibacterial 66592-87-8, 50370-12- 2091 A08 Microsource 01500163 CEFADROXIL antibacterial semisynthetic 2 [anhydrous], 119922- 89-9 [hemihydrate] Rheum palmatum, 2091 A09 Microsource 00211468 DANTHRON cathartic 117-10-2 Xyris semifuscata 27164-46-1, 25953-19- 2091 A10 Microsource 01500164 CEFAZOLIN SODIUM antibacterial semisynthetic 9 [cefazolin] glucocorticoid, 2091 A11 Microsource 00300024 HYDROCORTISONE adrenal glands 50-23-7 antiinflammatory 64485-93-4, 63527-52- 2091 A12 Microsource 01500165 CEFOTAXIME SODIUM antibacterial semisynthetic 6 [cefotaxime] 2091 A13 Microsource 00300029 DESOXYCORTICOSTERONE ACETATE mineralocorticoid adrenocortex 56-47-3 58-71-9, 153-61-7 2091 A14 Microsource 01500166 CEPHALOTHIN SODIUM antibacterial semisynthetic [cephalothin] 2091 A15 Microsource 00300034 TESTOSTERONE PROPIONATE androgen, antineoplastic semisynthetic 57-85-2 24356-60-3, 21593-23- 2091 A16 Microsource 01500167 CEPHAPIRIN SODIUM antibacterial semisynthetic 7 [cephapirin] 6160-12-9, 299-39-8 Lupinus spp and 2091 A17 Microsource 00300548 SPARTEINE SULFATE oxytocic [anhydrous], 90-39-1 other Leguminosae [sparteine] 38821-53-3 [anhydrous], 58456-86- 2091 A18 Microsource 01500168 CEPHRADINE antibacterial semisynthetic 3 [dihydrate], 31828- 50-9 [non- stoichiometric hydrate] Ruta graveolens, 2091 A19 Microsource 00300607 RUTOSIDE (rutin) vascular protectant 153-18-4 widespread in plants 6004-24-6, 123-03-5 2091 A20 Microsource 01500169 CETYLPYRIDINIUM CHLORIDE antiinfective (topical) synthetic [anhydrous] 2091 A21 Microsource 00300618 SALICYLANILIDE antipyretic, fungicide synthetic 87-17-2 antineoplastic, alkylating 2091 A22 Microsource 01500171 CHLORAMBUCIL synthetic 305-03-3 agent cardiotonic, 62-31-7, 51-61-6 2091 B03 Microsource 01500263 DOPAMINE HYDROCHLORIDE synthetic antihypotensive [dopamine] antineoplastic, alkylating 55-86-7, 51-75-2 2091 B04 Microsource 01500375 MECHLORETHAMINE synthetic agent [mechlorethamine] 1229-29-4, 1668-19-5 [doxepin], 4698-39-9 2091 B05 Microsource 01500264 DOXEPIN HYDROCHLORIDE antidepressant synthetic [(//E//)-isomer], 25127- 31-5 [(//Z//)-isomer] 31884-77-2, 1104-22- 2091 B06 Microsource 01500376 MECLIZINE HYDROCHLORIDE antiemetic synthetic 9 [anhydrous], 569-65- 3 [meclizine] semisynthetic; GS- 17086-28-1, 564-25-0 2091 B07 Microsource 01500266 DOXYCYCLINE HYDROCHLORIDE antibacterial 3065 [anhydrous] antiinflammatory, 2091 B08 Microsource 01500377 MECLOFENAMATE SODIUM synthetic 6385-02-0 antipyretic 562-10-7, 469-21-6 2091 B09 Microsource 01500267 DOXYLAMINE SUCCINATE antihistaminic, hypnotic synthetic [doxylamine] 71-58-9, 520-85-4 2091 B10 Microsource 01500379 MEDROXYPROGESTERONE ACETATE contraceptive semisynthetic [medroxyprogesterone ] 536-43-6, 586-60-7 2091 B11 Microsource 01500268 DYCLONINE HYDROCHLORIDE anesthetic (topical) synthetic [dyclonine] 2091 B12 Microsource 01500380 MEDRYSONE glucocorticoid semisynthetic 2668-66-8 PDE inhibitor, 2091 B13 Microsource 01500269 DYPHYLLINE bronchodilator, synthetic 479-18-5 vasodilator progestogen, 595-33-5, 3562-63-8 2091 B14 Microsource 01500381 MEGESTROL ACETATE semisynthetic antineoplastic [megestrol] TRISODIUM ETHYLENEDIAMINE chelating agent, 2091 B15 Microsource 01500270 synthetic 150-38-9 TETRACETATE antioxidant antineoplastic, alkylating 2091 B16 Microsource 01500382 MELPHALAN synthetic 148-82-3 agent Microsource1-US Drug Collection Page 1 of 24 Created 9/2015 ICCB-L ICCB-L Vendor Vendor Compound Name Bioactivity Source CAS Plate Well ID inhibits RNA, DNA and Uragoga 316-42-7, 483-18-1 2091 B17 Microsource 01500272 EMETINE protein synthesis ipecacuanha [emetine] 76-90-4, 25990-43-6 2091 B18 Microsource 01500383 MEPENZOLATE BROMIDE anticholinergic synthetic [mepenzolate] antirachitic vitamin; LD50 irradiation of 2091 B19 Microsource 01500276 ERGOCALCIFEROL 50-14-6 (rat) 56 mg/kg po ergosterol antineoplastic, purine 6112-76-1, 50-44-2 2091 B20 Microsource 01500387 MERCAPTOPURINE synthetic antimetabolite [anhydrous] ergot and 129-51-1, 60-79-7 2091 B21 Microsource 01500277 ERGONOVINE MALEATE oxytocic, 5HT antagonist Convolvulvaceae [ergonovine] spp estrogen, with 2091 B22 Microsource 01500388 MESTRANOL progesterone as oral semisynthetic 72-33-3 contraceptive antibacterial synthetic; NSC- 2091 C03 Microsource 00305025 PHENYL AMINOSALICYLATE 133-11-9 (tuberculostatic) 40144 antibacterial, 2091 C04 Microsource 01500172 CHLORAMPHENICOL PALMITATE semisynthetic 530-43-8 antirickettsial mamallian male 2091 C05 Microsource 00307023 TESTOSTERONE androgen, antineoplastic 58-22-0 hormone antibacterial, 982-57-0, 56-75-7 2091 C06 Microsource 01500173 CHLORAMPHENICOL HEMISUCCINATE antirickettsial, inhibits semisynthetic [chloramphenicol] protein synthesis derivative of cardiotonic, uterine 4884-68-8, 6592-85-4 2091 C07 Microsource 00310006 HYDRASTININE HYDROCHLORIDE hydrastine hemostatic [hydrastinine] (01501009) antibacterial, Streptomyces 2091 C08 Microsource 01500174 CHLORAMPHENICOL antirickettsial, inhibits 56-75-7 venezuelae protein synthesis antineoplastic, antiplaque Sanguinaria 2091 C09 Microsource 00310035 SANGUINARINE SULFATE 5578-73-4 agent canadensis 1620-21-9, 82-93-9 2091 C10 Microsource 01500175 CHLORCYCLIZINE HYDROCHLORIDE H1-antihistamine synthetic [base] soya, wheat germ 2091 C11 Microsource 00310039 alpha-TOCHOPHEROL vitamin E 59-02-9 and other plant oils antibacterial (topical), 3697-42-5, 55-56-1 2091 C12 Microsource 01500177 CHLORHEXIDINE synthetic disinfectant [chlorhexidine] 2091 C13 Microsource 00310040 alpha-TOCHOPHERYL ACETATE vitamin E derivative 58-95-7 2091 C14 Microsource 01500178 CHLOROCRESOL antiinfectant synthetic 59-50-7 2091 C15 Microsource 00310050 QUININE ETHYL CARBONATE antimalarial semisynthetic 83-75-0 antimalarial, antiamebic, 2091 C16 Microsource 01500179 CHLOROQUINE DIPHOSPHATE antirheumatic, synthetic 54-05-7 intercalating agent antineoplastic, 2091 C17 Microsource 00330001 DACTINOMYCIN Actinomyces spp 50-76-0 intercalating agent 2091 C18 Microsource 01500180 CHLOROTHIAZIDE diuretic, antihypertensive synthetic 58-94-6 Streptomyces 2091 C19 Microsource 00330002 MITOMYCIN C antineoplastic 50-07-7 verticillatus 2091 C20 Microsource 01500181 CHLOROTRIANISENE estrogen synthetic 569-57-3 insecticide, 2091 C21 Microsource 00330018 DICHLORVOS synthetic 62-73-7 cholinesterase inhibitor antibacterial, topical and 2091 C22 Microsource 01500182 CHLOROXYLENOL synthetic 88-04-0 urinary antiseptic 1264-62-6, 114-07-8 2091 D03 Microsource 01500279 ERYTHROMYCIN ETHYLSUCCINATE antibacterial semisynthetic [erythromycin] 586-06-1, 5874-97-5 2091 D04 Microsource 01500390 METAPROTERENOL bronchodilator synthetic [metaproterenol sulfate] Streptomyces 2091 D05 Microsource 01500280 ERYTHROMYCIN antibacterial 114-07-8 erythreus cholinergic, diagnostic 62-51-1, 55-92-5 2091 D06 Microsource 01500391 METHACHOLINE CHLORIDE synthetic aid [methacholine] 2091 D07 Microsource 01500282 ESTRADIOL estrogen pregnancy urine 50-28-2 2091 D08 Microsource 01500394 METHENAMINE antibacterial (urinary) synthetic 100-97-0 2091 D09 Microsource 01500283 ESTRADIOL CYPIONATE estrogen semisynthetic 313-06-4 7246-14-2, 132-92-3 2091 D10 Microsource 01500395 METHICILLIN SODIUM antibacterial semisynthetic [anhydrous], 61-32-5 [methicillin] 2091 D11 Microsource 01500284 ESTRADIOL VALERATE estrogen semisynthetic 979-32-8 2091 D12 Microsource 01500396 METHIMAZOLE antihyperthyroid synthetic 60-56-0 mammalian 50-27-1, 514-68-1 [as, 2091 D13 Microsource 01500285 ESTRIOL estrogen hormone succinate] muscle relaxant 2091 D14 Microsource 01500397 METHOCARBAMOL synthetic 532-03-6 (skeletal) Microsource1-US Drug Collection Page 2 of 24 Created 9/2015 ICCB-L ICCB-L Vendor Vendor Compound Name Bioactivity Source CAS Plate Well ID pregnacy urine, 2091 D15 Microsource 01500286 ESTRONE estrogen dates and Punica 53-16-7 granatum seeds antineoplastic, synthetic; 2091 D16 Microsource 01500398 METHOTREXATE(+/-) antirheumatic, folic acid 60388-53-6 AMETHOPTERIN antagonist 2091 D17 Microsource 01500287 ETHACRYNIC ACID diuretic synthetic 58-54-8 alpha1 adrenoreceptor 61-16-5, 390-28-3 2091 D18 Microsource 01500399 METHOXAMINE HYDROCHLORIDE synthetic agonist, vasoconstrictor [methoxamine] antibacterial 1070-11-7, 74-55-5 2091 D19 Microsource 01500288 ETHAMBUTOL HYDROCHLORIDE synthetic (tuberculostatic) [ethambutol] antipsoriatic, 2091 D20 Microsource 01500400 METHOXSALEN amni visnaga 298-81-7 pigmentation agent estrogen, plus 2091 D21 Microsource 01500291 ETHINYL ESTRADIOL progestogen as oral semisynthetic 57-63-6 contraceptive 2091 D22 Microsource 01500401 METHSCOPOLAMINE BROMIDE anticholinergic semisynthetic 155-41-9 2091 E03 Microsource 00330062 TEMEFOS insecticide synthetic 3383-96-8 113-92-8, 132-22-9 2091 E04 Microsource 01500183 CHLORPHENIRAMINE (S) MALEATE antihistaminic synthetic [chlorpheniramine] synthetic; gamma- 2091 E05 Microsource 00330071 LINDANE insecticide 58-89-9 BHC 2091 E06 Microsource 01500184 CHLORPROMAZINE antiemetic, antipsychotic synthetic 50-53-3
Recommended publications

  • Europæisk Patentskrift

    (19) DANMARK (1°) DK/EP 2968225 T3 (12) Oversættelse af europæisk patentskrift Patent- og Varemærkestyrelsen (51) lnt.CI.: A 61 K 31/137 (2006.01) A 61 K 9/00 (2006.01) A 61 K 31/245 (2006.01) A 61 K 31/445 (2006.01) A 61 K 31/519 (2006.01) A 61 K 31/52 (2006.01) A 61 P 43/00 (2006.01) (45) Oversættelsen bekendtgjort den: 2019-05-27 (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: 2019-02-20 (86) Europæisk ansøgning nr.: 14719486.4 (86) Europæisk indleveringsdag: 2014-03-17 (87) Den europæiske ansøgnings publiceringsdag: 2016-01-20 (86) International ansøgning nr.: US2014030372 (87) Internationalt publikationsnr.: WO2014145580 (30) Prioritet: 2013-03-15 US 201361789054 P (84) Designerede stater: AL AT BE BG CH CY CZ DE DK EE ES Fl FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (73) Patenthaver: The Children's Medical Center Corporation, 55 Shattuck Street, Boston, Massachusetts 02115, USA (72) Opfinder: BERDE, Charles, 14 Doran Road, Bookline, MA 02146, USA KOHANE, Daniel S., 119 Willard Street, Newton, MA 02461, USA (74) Fuldmægtig i Danmark: AWA Denmark A/S, Strandgade 56,1401 København K, Danmark (54) Benævnelse: NEOSAXITOXINKOMBINATIONSFORMULERINGER TIL FORLÆNGET LOKALANÆSTESI (56) Fremdragne publikationer: WO-A2-98/51290 ALBERTO J. RODRIGUEZ-NAVARRO ET AL: "Potentiation of Local Anesthetic Activity of Neosaxitoxin with Bupivacaine or Epinephrine: Development of a Long-Acting Pain Blocker", NEUROTOXICITY RESEARCH, vol. 16, no. 4, 28 July 2009 (2009-07-28), pages 408-415, XP055122925, ISSN: 1029-8428, DOI: 10.1007/s12640-009- 9092-3 cited in the application Anonymous: "NCT01786655 on 2013_02_11: ClinicalTrials.gov Archive",, 11 February 2013 (2013-02-11), XP055122935, Retrieved from the Internet: URL:http://clinicaltrials.gov/archive/NCTO 1786655/2013_02_11 [retrieved on 2014-06-12] CHARLES B.
  • Antiseptics and Disinfectants for the Treatment Of

    Antiseptics and Disinfectants for the Treatment Of

    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications

    Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications

    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
  • PEMD-91-12BR Off-Label Drugs: Initial Results of a National Survey

    PEMD-91-12BR Off-Label Drugs: Initial Results of a National Survey

    11 1; -- __...._-----. ^.-- ______ -..._._ _.__ - _........ - t Ji Jo United States General Accounting Office Washington, D.C. 20648 Program Evaluation and Methodology Division B-242851 February 25,199l The Honorable Edward M. Kennedy Chairman, Committee on Labor and Human Resources United States Senate Dear Mr. Chairman: In September 1989, you asked us to conduct a study on reimbursement denials by health insurers for off-label drug use. As you know, the Food and Drug Administration designates the specific clinical indications for which a drug has been proven effective on a label insert for each approved drug, “Off-label” drug use occurs when physicians prescribe a drug for clinical indications other than those listed on the label. In response to your request, we surveyed a nationally representative sample of oncologists to determine: . the prevalence of off-label use of anticancer drugs by oncologists and how use varies by clinical, demographic, and geographic factors; l the extent to which third-party payers (for example, Medicare intermediaries, private health insurers) are denying payment for such use; and l whether the policies of third-party payers are influencing the treatment of cancer patients. We randomly selected 1,470 members of the American Society of Clinical Oncologists and sent them our survey in March 1990. The sam- pling was structured to ensure that our results would be generalizable both to the nation and to the 11 states with the largest number of oncologists. Our response rate was 56 percent, and a comparison of respondents to nonrespondents shows no noteworthy differences between the two groups.
  • Identification of Candidate Agents Active Against N. Ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N

    Identification of Candidate Agents Active Against N. Ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N

    RESEARCH ARTICLE Identification of Candidate Agents Active against N. ceranae Infection in Honey Bees: Establishment of a Medium Throughput Screening Assay Based on N. ceranae Infected Cultured Cells Sebastian Gisder, Elke Genersch* Institute for Bee Research, Department of Molecular Microbiology and Bee Diseases, Hohen Neuendorf, Germany * [email protected] Abstract OPEN ACCESS Many flowering plants in both natural ecosytems and agriculture are dependent on insect Citation: Gisder S, Genersch E (2015) Identification of Candidate Agents Active against N. ceranae pollination for fruit set and seed production. Managed honey bees (Apis mellifera) and wild Infection in Honey Bees: Establishment of a Medium bees are key pollinators providing this indispensable eco- and agrosystem service. Like all Throughput Screening Assay Based on N. ceranae other organisms, bees are attacked by numerous pathogens and parasites. Nosema apis is Infected Cultured Cells. PLoS ONE 10(2): e0117200. a honey bee pathogenic microsporidium which is widely distributed in honey bee popula- doi:10.1371/journal.pone.0117200 tions without causing much harm. Its congener Nosema ceranae was originally described Academic Editor: Wolfgang Blenau, Goethe as pathogen of the Eastern honey bee (Apis cerana) but jumped host from A. cerana to A. University Frankfurt, GERMANY mellifera about 20 years ago and spilled over from A. mellifera to Bombus spp. quite recent- Received: October 8, 2014 ly. N. ceranae is now considered a deadly emerging parasite of both Western honey bees Accepted: December 20, 2014 and bumblebees. Hence, novel and sustainable treatment strategies against N. ceranae are Published: February 6, 2015 urgently needed to protect honey and wild bees.
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub

    US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults.
  • 1 Brief Report: the Virucidal Efficacy of Oral Rinse Components Against SARS-Cov-2 in Vitro Evelina Statkute1†, Anzelika Rubin

    1 Brief Report: the Virucidal Efficacy of Oral Rinse Components Against SARS-Cov-2 in Vitro Evelina Statkute1†, Anzelika Rubin

    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro Evelina Statkute1†, Anzelika Rubina1†, Valerie B O’Donnell1, David W. Thomas2† Richard J. Stanton1† 1Systems Immunity University Research Institute, Division of Infection & Immunity, School of Medicine, Heath Park, Cardiff, CF14 4XN 2Advanced Therapies Group, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, UK †These authors contributed equally * Correspondence: [email protected], [email protected] Running title: Virucidal Activity of Mouthwashes Keywords: SARS-CoV2, mouthwash, lipid, envelope Disclosure: Venture Life Group plc provided information on mouthwash formulations employed in the study, but had no role in funding, planning, execution, analysis or writing of this study. A separate study funded to Cardiff University by Venture Life Group is assessing in vivo efficacy of CPC in patients with COVID19. The investigators declare no direct conflicts exist. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.
  • Lymphoid Organs of Neonatal and Adult Mice Preferentially Produce Active Glucocorticoids from Metabolites, Not Precursors ⇑ Matthew D

    Lymphoid Organs of Neonatal and Adult Mice Preferentially Produce Active Glucocorticoids from Metabolites, Not Precursors ⇑ Matthew D

    Brain, Behavior, and Immunity 57 (2016) 271–281 Contents lists available at ScienceDirect Brain, Behavior, and Immunity journal homepage: www.elsevier.com/locate/ybrbi Full-length Article Lymphoid organs of neonatal and adult mice preferentially produce active glucocorticoids from metabolites, not precursors ⇑ Matthew D. Taves a,b, , Adam W. Plumb c, Anastasia M. Korol a, Jessica Grace Van Der Gugten d, Daniel T. Holmes d, Ninan Abraham b,c,1, Kiran K. Soma a,b,e,1 a Department of Psychology, University of British Columbia, 2136 West Mall, Vancouver V6T 1Z4, Canada b Department of Zoology, University of British Columbia, 4200-6270 University Blvd, Vancouver V6T 1Z4, Canada c Department of Microbiology and Immunology, University of British Columbia, 1365-2350 Health Sciences Mall, Vancouver V6T 1Z3, Canada d Department of Laboratory Medicine, St Paul’s Hospital, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada e Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada article info abstract Article history: Glucocorticoids (GCs) are circulating adrenal steroid hormones that coordinate physiology, especially the Received 4 March 2016 counter-regulatory response to stressors. While systemic GCs are often considered immunosuppressive, Received in revised form 22 April 2016 GCs in the thymus play a critical role in antigen-specific immunity by ensuring the selection of competent Accepted 7 May 2016 T cells. Elevated thymus-specific GC levels are thought to occur by local synthesis, but the mechanism of Available online 7 May 2016 such tissue-specific GC production remains unknown. Here, we found metyrapone-blockable GC produc- tion in neonatal and adult bone marrow, spleen, and thymus of C57BL/6 mice.
  • Quaternary Ammonium Compounds

    Quaternary Ammonium Compounds

    FACT SHEET: Quaternary Ammonium Compounds Quaternary ammonium compounds, also known as “quats” or “QACs,” include a number of chemicals used as sanitizers and disinfectants, including benzalkonium chloride, benzethonium chloride, cetalkonium chloride, cetrimide, cetrimonium bromide, cetylpyridinium chloride, glycidyl trimethyl, ammonium chloride, and stearalkonium chloride.[i] In general, quats cause toxic effects through all Mutagenicity routes of exposure including inhalation, Some quats have shown to be mutagenic and to ingestion, dermal application, and irrigation of damage animal DNA and DNA in human body cavities. Exposure to diluted solutions may lymphocytes at much lower levels than are result in mild irritation, while concentrated present in cleaning chemicals.[6] solutions are corrosive, causing burns to the skin and mucous Membranes. They can produce Antimicrobial Resistance systemic toxicity and can also cause allergic Genes have been discovered that mediate reactions.[2] resistance to quats. There has been an association of some of these genes with beta lactamase genes, Asthma and Allergies raising concern for a relationship between Of particular interest with regard to use as disinfectant resistance and antibiotic resistance.[7] disinfectants in the COVID-19 pandemic, quats increase the risk for asthma and allergic Reproductive Toxicity sensitization. Evidence from occupational Mice whose cages were cleaned with QACs had exposures shows increased risk of rhinitis and very low fertility rates. [8] Exposure to a common asthma
  • Summary of Product Characteristics

    Summary of Product Characteristics

    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Aldactone 50 mg Film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg of Spironolactone. For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet (Tablets) Round, white coloured, biconvex tablet with a peppermint odour embossed ‘SEARLE over 916’ on one side and the other side plain. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. Children should only be treated under guidance of a paediatric specialist. There is limited paediatric data available (see sections 5.1 and 5.2). 4.2 Posology and method of administration Administration of Aldactone once daily with a meal is recommended. Posology Adults Congestive heart failure: Usual dose - 100 mg/day. In difficult or severe cases the dosage may be gradually increased up to 200 mg/day. When oedema is controlled, the usual maintenance level is 75 mg/day to 200 mg/day. Severe heart failure in conjunction with standard therapy (New York Heart Association Class III-IV): Based on the Randomized Aldactone Evaluation Study (RALES), treatment in conjunction with standard therapy should be initiated at a dose of spironolactone 25 mg once daily in patients with a serum potassium ≤5.0 mEq/L and serum creatinine ≤2.5 mg/dL. Patients who tolerate 25 mg once daily may have their dose increased to 50 mg once daily as clinically indicated.
  • NINDS Custom Collection II

    NINDS Custom Collection II

    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
  • In Vivo Evaluation of the Virucidal Efficacy of Chlorhexidine and Povidone-Iodine Mouthwashes Against Salivary SARS-Cov-2

    In Vivo Evaluation of the Virucidal Efficacy of Chlorhexidine and Povidone-Iodine Mouthwashes Against Salivary SARS-Cov-2

    medRxiv preprint doi: https://doi.org/10.1101/2021.03.07.21252302; this version posted March 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title: In vivo evaluation of the virucidal efficacy of Chlorhexidine and Povidone-iodine mouthwashes against salivary SARS-CoV-2. Rola Elzein1*, Fadi Abdel-Sater2*, Soha Fakhreddine3, Pierre Abi Hanna3, Rita Feghali4, Hassan Hamad5, Fouad Ayoub6 ¹Department of Pediatric Dentistry and Public Dental Health, Faculty of Dental Medicine, Lebanese University, Beirut, Lebanon 2Laboratory of Cancer Biology and Cellular Immunology, Department of Biological Sciences, Faculty of Sciences, Lebanese University, Beirut, Lebanon 3Infectious Diseases division, Rafik Hariri University Hospital, Beirut, Lebanon 4Department of Laboratory Medicine, Rafik Hariri University Hospital, Beirut, Lebanon 5Medical care Laboratory, Faculty of Public Health IV, Lebanese University, Zahle, Lebanon 6Department of Forensic Odontology, Human Identification and Anthropology, Faculty of Dental Medicine, Lebanese University, Beirut, Lebanon *CORRESPONDING AUTHORS: Rola ELZEIN; Mobile number: 009613252480; Email address: [email protected] Fadi Abdelsater; Mobile number: 009613781176; Email address: [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.03.07.21252302; this version posted March 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.